ASPR announces investment to increase domestic production of essential drugs
The Administration for Strategic Preparedness and Response Feb. 18 announced an investment that will focus on resolving a frequent shortage of oseltamivir, also known as Tamiflu. The investment is ASPR’s first under the Department of Health and Human Services-designated Defense Production Act Title III program, which is intended to strengthen the U.S. public health supply chain and reduce reliance on foreign resources by increasing the domestic production of essential medications and their active pharmaceutical ingredients. ASPR said Manus Bio Inc., based in Waltham, Mass., will expand its facilities in Augusta, Ga., to produce shikimic acid, a key ingredient for the drug.
Related News Articles
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Perspective
A highly qualified and engaged workforce is at the heart of America’s health care system. Yet the U.S. faces significant shortages of health care workers…
Headline
The Department of Homeland Security today released a proposed rule to amend the process for selecting among prospective applicants — known as registrants — for…
Headline
The AHA and Federation of American Hospitals yesterday filed a friend-of-the-court brief in the U.S. Court of Appeals for the 5th Circuit, urging the court to…
Perspective
Hospitals and health systems are cornerstones of communities across our nation. The more than 6 million people who work there provide care, compassion and…